UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 9th, 2016
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-52403 | 20-3373669 |
(State of incorporation) | (Commission File Number) | (IRS Employer No.) |
#3 Bethesda Metro Center
Suite 700
Bethesda, MD 20814
(Address of principal executive offices and Zip Code)
(877) 424-2429
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On December 9th, 2016, Mr. Dov Weinberg resigned his position as Chief Financial Officer of the Corporation. This decision was not the result of any disagreement with the Company.
On the same day the Company appointed Mr. Uri Ben-Or as Chief Financial Officer of the Corporation. Mr. Ben-Or, 46, has over 20 years of broad experience in corporate finance, accounting, M&A transactions, IPO's and operations.
Mr. Ben-Or is CEO & Founder of one of the few financial firms in Israel to have the International Standard on Assurance Engagement (ISAE 3402/SAS 70 Type II) assurance with control compliances, the new global standard for assurance reporting. He previously served as an Auditor at PricewaterhouseCoopers Accounting Firm.
Mr. Ben-Or holds a BA degree in Business from the College of Administration, an MBA degree from the Bar Ilan University and is a Certified Public Accountant.
ITEM 9.01 FINANICAL STATEMENTS & EXHIBITS
(d) Exhibits
99.1 | Resignation of Mr. Weinberg | |
99.2 | Board of Director Resolution naming Uri Ben-Or as CFO |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 13, 2016
Cannabics Pharmaceuticals Inc. | |
By: /s/ Itamar Borochov | |
Itamar Borochov, Director, CEO |
3 |
Exhibit 99.1
RESIGNATION OF
CHIEF FINANCIAL OFFICER
OF
CANNABICS PHARMACEUTICALS INC.
The following is a true copy of the Chief Financial Officer’s Resignation from the Corporation, held this 9 th , December 2016;
WHEREAS the undersigned was appointed as Chief Financial Officer of the Corporation and has served in said capacity to date, he has determined at this time to formally RESIGN and renounce all further corporate designation or affiliation with CANNABICS PHARMACEUTICALS INC. and hereby formally RESIGNS, and severs any and all officials ties, duties, obligations or liabilities regarding CANNABICS PHARMACEUTICALS INC. , and does hereby, by affixing, his signature hereto, officially as his last corporate act, DOES HEREBY RESIGN. This Resignation is not the result of any dispute with management.
The Board shall choose a new Chief Financial Officer at a time and place of its choosing.
DATED: 9 th , December, 2016
/s/ DOV WEINBERG
DOV WEINBERG, CFO
CANNABICS PHARMACEUTICALS INC.
Exhibit 99.2
THE BOARD OF DIRECTORS
OF
CANNABICS PHARMACEUTICALS INC.
The following is a true copy of the resolution duly adopted by the Board of Directors of this Corporation at a special meeting, notice to this meeting having been waived, held on this 9th day of December, 2016;
The Board of Directors which was present for this meeting & took active part therein was:
Eyal Ballan
Itamar Borochov
WHEREAS there has been presented to and considered by this meeting a Motion to appoint a new Chief Financial Executive in light of the Resignation of our current Chief Financial Executive Dov Weinberg;
NOW THEREFORE BE IT RESOLVED that the Board of Directors, having considered this matter, and having opened the floor to all those who voice a preference in the issue, and pursuant to §NRS 78.315, have decided unanimously and RESOLVED that:
The Company hereby appoints URI BEN-OR as our Chief Financial Executive, effective immediately.
Said Motion is hereby passed and the corporate books, records and the Secretary shall file this Resolution in the corporate records
DATED: 9th December, 2016
/s/ Itamar Borochov
Itamar Borochov, Director, CEO